29 October 2015

The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for IMLYGIC™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy for patients with a serious form of skin cancer. EU approval for IMLYGIC™ is expected during the next few months.

Biovex is a pioneering biotechnology company which created a new class of potent biologics for the treatment of cancer and prevention of infectious disease. Biovex was spun-out of UCL and acquired in January 2011 by US biotechnology giant Amgen Inc.

For the full article, read here. http://www.amgen.com/media/news-releases/2015/10/fda-approves-imlygic-talimogene-laherparepvec-as-first-oncolytic-viral-therapy-in-the-us/

Links
Biovex